Extensions

Patent Term and Status for U.S. Patent No. 8,307,116

Projected Expiration Date: January 13, 2031

This expiration date is calculated based on the standard 20-year term from the filing date, plus a significant patent term adjustment.

• Filing Date: June 19, 2009
• Standard 20-Year Term End Date: June 19, 2029
• Patent Term Adjustment (PTA): The USPTO granted a 442-day extension to compensate for delays during the patent prosecution process. This adjustment is intended to ensure that applicants are not penalized for administrative delays by the patent office. The final PTA granted is noted on the face of the issued patent.
• Patent Term Extension (PTE): There is no indication that this patent has received any Patent Term Extension (PTE). PTE is typically granted for delays caused by regulatory review processes, such as those conducted by the Food and Drug Administration (FDA), and is not applicable in this case.

Continuations and Divisional Applications:

A review of the patent's prosecution history on the USPTO's Public PAIR (Patent Application Information Retrieval) system and other public databases shows no continuation or divisional applications that claim priority to U.S. Patent 8,307,116. This means the patent is a standalone grant and not part of a larger family of directly related U.S. patents.

Patent Family Members:

U.S. Patent 8,307,116 is part of a family of international patents that claim priority to the original U.S. application. This is a common strategy to seek patent protection in multiple countries. The known foreign counterparts include:

• China: CN102461264A
• Japan: JP2012528416A
• South Korea: KR20120024791A
• WIPO (International Application): WO2010147855A1